Regulation

We appreciate the FCC’s aggressive efforts to protect consumer interests and ensure that out-of-control local governments don’t erect counterproductive barriers to increased adoption of broadband services throughout the country.

Senator Ron Wyden (D-Oregon) wants to cap seniors' drug costs in Medicare Part D, but not everyone sees positives to that plan.

Imposing back-door price controls is bad news for seniors. 

If Johnson can resist the demands of progressive constituencies to impose a social agenda on the people of Dallas, and if he will simply focus on doing a great job of running the core duties of the city, he can count on the support of Dallasites of all political persuasions, and in the process redefine Democratic urban governance, making Dallas a model for cities across the nation.

Plans for a privately financed, high-speed rail line between Houston and Dallas are being challenged by members of the Texas State Legislature, landowners along the proposed route, and some transportation researchers.

One year after the FCC’s reversal of the Obama administration’s heavy-handed internet regulations, not only did the sky not fall but investment is up, fiber and wireless are accelerating, and the broadband economy is back on the right track.

In an effort to improve the science used by regulatory agencies, the Trump administration has made, and is still making, adjustments in the way the Environmental Protection Agency (EPA) and other agencies approach climate change and make the predictions that drive climate policies. Not everyone is pleased, to put it mildly.

“A lot of these licensing programs exist for no other reason than to protect a professional cartel and keep out competition," said IPI president Tom Giovanetti.

A new Health and Human Services rule requiring pharmaceutical companies to disclose list prices for medications in commercial advertisements is unlikely to boost price transparency for consumers. In fact, it may create even more confusion.

If lawmakers want to cut drug spending without leaving patients in the lurch, they’d be wise to foster more competition in the drug marketplace. Price controls are more about limiting access than price.